FR2621818A1 - MEDICINE COMPRISING THE COMBINATION OF POLYMIXIN B, NETILMICIN AND AMPHOTERICIN B BY VAPORIZATION - Google Patents
MEDICINE COMPRISING THE COMBINATION OF POLYMIXIN B, NETILMICIN AND AMPHOTERICIN B BY VAPORIZATION Download PDFInfo
- Publication number
- FR2621818A1 FR2621818A1 FR8714346A FR8714346A FR2621818A1 FR 2621818 A1 FR2621818 A1 FR 2621818A1 FR 8714346 A FR8714346 A FR 8714346A FR 8714346 A FR8714346 A FR 8714346A FR 2621818 A1 FR2621818 A1 FR 2621818A1
- Authority
- FR
- France
- Prior art keywords
- nasal
- precise
- spraying
- dispensed
- amphotericin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Description
lut ente Invention (concerne un médicament pour vaporise+zon destinëL prévenir leS risques d'infection criez les malades à risques en décontaminant e cd'vités nasales et oropharyngées. lut ente Invention (concerns a medicine for spray + zone intended to prevent the risks of infection shout out patients at risk by decontaminating their nasal and oropharyngeal guests.
Les infections à bacilles gram négatif et les mycoses sont fréquentes chez 3e malades à risques . Elles entralnent une morbidité importante , elles sont une des' causes principales du décès de ces patients , elles augmentent les dépenses de santé en augmentant les durées d'hospitalisation
La présente invention permet de remédier à cet inconvénient . Elle comporte l'association de trois antibiotiques administrée par vaporisation dans les cavités nasales et orophryngées . Les trois antibiotiques associés dans la préparation sont la polymyxine B , la netilmitine et l'amphotéricine B .La préparation doit adhérer aux muqueuses nasales et buccales , relarguer lentement les antibiotiques et avoir une tension superficielle permettant un talenient maximal sur les muqueuses nasales et oropharyngées . La préparation est administrée par vaporisation précise soit sous forme d'aérosol pressurisé distribué par une valve continue ou doseuse soit sous forme de nébulisation distribuée par une pompe précise . Deux poussoirs sont fournis avec chaque flacon : l'un disposant d'une canule longue et fine permettant l'introduction par les narines et la vaporisation des fosses nasales , l'autre d'une canule permettant une vaporisation large de la cavité oropharyngée .Infections with gram-negative bacilli and yeast infections are frequent in 3rd patients at risk. They cause significant morbidity, they are one of the 'main causes of death of these patients, they increase healthcare costs by increasing the length of hospital stays
The present invention overcomes this drawback. It involves the combination of three antibiotics administered by spraying into the nasal and orophryngeal cavities. The three antibiotics associated in the preparation are polymyxin B, netilmitine and amphotericin B. The preparation must adhere to the nasal and oral mucous membranes, slowly release the antibiotics and have a surface tension allowing maximum talenient on the nasal and oropharyngeal mucous membranes. The preparation is administered by precise spraying either in the form of a pressurized aerosol dispensed by a continuous or metering valve or in the form of a nebulization dispensed by a precise pump. Two pushers are supplied with each bottle: one with a long and fine cannula allowing the introduction through the nostrils and vaporization of the nasal cavities, the other with a cannula allowing a broad vaporization of the oropharyngeal cavity.
Les doses distribuées par les valves ou les pompes seront tres précises
Elles sont bien entendu fonction de la concentration des antibiotiques au sein de la préparation
La fréquence des applications dépend également de la concentration de ces produits.The doses distributed by the valves or the pumps will be very precise
They are of course a function of the concentration of antibiotics within the preparation
The frequency of applications also depends on the concentration of these products.
Aucun de ces antibiotiques n'étant absorbé par voie nasale , oropharyngée ou digestive , les posologies et donc les concentrations peuvent varier dans une très large part
Les caractéristiques et avantages de l'invention ressortent de la description qui va suivre à titre d'exemple : pour 30 ml de préparation , on associe
-sulfate de polymyxine B : 500 mg -sulfate de nétilmi cine : 450 450 mg
-amphotéricine B : 2500 mg
-alcool à 900 : 1 ml
-saccharinate de sodium : 100 mg
-essence de menthe : 0,02ml
-glycérine : quantité suffisante pour 30 ml
La valve ou la pompe doit hêtre adaptée pour délivrer 0,5 ml à chaque preF- slow. . On recommande 6 pressions dans la cavité oropharyngée , 3 pressions dans chaque narine à chaque administration et une fréquence de quatre administrations par jour . Dans cet exemple , on administre 400 mg de polymyxine b ,360 mg de nétilmicine et 2000 mg d' amphotéricine B par jour
Ilest recommandé d'associer la vaporisation nasale et oropharyngée à une décontamination sélective du tube digestif par administration orale ou par sonde gastrique avec ces mêmes antibiotiques.None of these antibiotics being absorbed via the nasal, oropharyngeal or digestive route, the dosages and therefore the concentrations can vary to a very large extent.
The characteristics and advantages of the invention appear from the description which follows by way of example: for 30 ml of preparation, one associates
- polymyxin B sulfate: 500 mg - netilmi cine sulfate: 450 450 mg
-amphotericin B: 2500 mg
- 900 alcohol: 1 ml
-sodium saccharinate: 100 mg
-mint essence: 0.02ml
-glycerin: sufficient quantity for 30 ml
The valve or pump must be suitable for delivering 0.5 ml for each pre-slow. . We recommend 6 pressures in the oropharyngeal cavity, 3 pressures in each nostril with each administration and a frequency of four administrations per day. In this example, 400 mg of polymyxin b, 360 mg of netilmicin and 2000 mg of amphotericin B are administered daily
It is recommended to combine nasal and oropharyngeal spraying with selective decontamination of the digestive tract by oral administration or by gastric tube with these same antibiotics.
Les indications de ce médicament sont très larges : ildoit être employé chaque fois qu'un risque d'infection à gram négatif ou de mycose est présent: en réanimation , en hématologie , en chirurgie ,en anesthésiologie , en cancérologie , etc... The indications for this drug are very broad: it must be used whenever a risk of gram negative infection or mycosis is present: in intensive care, hematology, surgery, anesthesiology, oncology, etc ...
Claims (4)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8714346A FR2621818B1 (en) | 1987-10-19 | 1987-10-19 | MEDICINE COMPRISING THE COMBINATION OF POLYMIXIN B, NETILMICIN AND AMPHOTERICIN B BY VAPORIZATION |
| AU26248/88A AU2624888A (en) | 1987-10-19 | 1988-10-19 | Drug comprising the association of polymyxin b, netilmycin and amphotericin b, administered by spraying |
| PCT/FR1988/000512 WO1989003672A1 (en) | 1987-10-19 | 1988-10-19 | Drug comprising the association of polymyxin b, netilmycin and amphotericin b, administered by spraying |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8714346A FR2621818B1 (en) | 1987-10-19 | 1987-10-19 | MEDICINE COMPRISING THE COMBINATION OF POLYMIXIN B, NETILMICIN AND AMPHOTERICIN B BY VAPORIZATION |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2621818A1 true FR2621818A1 (en) | 1989-04-21 |
| FR2621818B1 FR2621818B1 (en) | 1990-12-14 |
Family
ID=9355911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8714346A Expired - Lifetime FR2621818B1 (en) | 1987-10-19 | 1987-10-19 | MEDICINE COMPRISING THE COMBINATION OF POLYMIXIN B, NETILMICIN AND AMPHOTERICIN B BY VAPORIZATION |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2624888A (en) |
| FR (1) | FR2621818B1 (en) |
| WO (1) | WO1989003672A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4440391C1 (en) * | 1994-11-11 | 1996-05-09 | Haider Angelika | Use of aminoglycosides for the diagnosis of barrier disorders |
| EP2077132A1 (en) | 2008-01-02 | 2009-07-08 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dispensing device, storage device and method for dispensing a formulation |
| US10011906B2 (en) | 2009-03-31 | 2018-07-03 | Beohringer Ingelheim International Gmbh | Method for coating a surface of a component |
| EP2432531B1 (en) | 2009-05-18 | 2019-03-06 | Boehringer Ingelheim International GmbH | Adapter, inhalation device and nebulizer |
| US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
| WO2011064163A1 (en) | 2009-11-25 | 2011-06-03 | Boehringer Ingelheim International Gmbh | Nebulizer |
| AP3141A (en) | 2009-11-25 | 2015-02-28 | Boehringer Ingelheim Int | Nebulizer |
| US9943654B2 (en) | 2010-06-24 | 2018-04-17 | Boehringer Ingelheim International Gmbh | Nebulizer |
| EP2694220B1 (en) | 2011-04-01 | 2020-05-06 | Boehringer Ingelheim International GmbH | Medical device comprising a container |
| US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
| WO2013152894A1 (en) | 2012-04-13 | 2013-10-17 | Boehringer Ingelheim International Gmbh | Atomiser with coding means |
| EP3030298B1 (en) | 2013-08-09 | 2017-10-11 | Boehringer Ingelheim International GmbH | Nebulizer |
| ES2836977T3 (en) | 2013-08-09 | 2021-06-28 | Boehringer Ingelheim Int | Nebulizer |
| WO2015169430A1 (en) | 2014-05-07 | 2015-11-12 | Boehringer Ingelheim International Gmbh | Nebulizer |
| JP6580070B2 (en) | 2014-05-07 | 2019-09-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Container, nebulizer, and use |
| WO2015169429A2 (en) | 2014-05-07 | 2015-11-12 | Boehringer Ingelheim International Gmbh | Container, indicator device, and nebulizer |
| RU2605263C1 (en) * | 2015-11-05 | 2016-12-20 | государственное автономное научное учреждение "Институт стратегических исследований Республики Башкортостан" | Ointment with netilmicin and propolis extract for integrated treating inflammatory periodontal diseases |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL121455C (en) * | 1900-01-01 | |||
| GB1018125A (en) * | 1962-11-29 | 1966-01-26 | Merck & Co Inc | Chemical products |
| AU539563B2 (en) * | 1981-01-21 | 1984-10-04 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara | Primycin, doxycyline and sisomicin composition |
-
1987
- 1987-10-19 FR FR8714346A patent/FR2621818B1/en not_active Expired - Lifetime
-
1988
- 1988-10-19 WO PCT/FR1988/000512 patent/WO1989003672A1/en unknown
- 1988-10-19 AU AU26248/88A patent/AU2624888A/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL121455C (en) * | 1900-01-01 | |||
| GB1018125A (en) * | 1962-11-29 | 1966-01-26 | Merck & Co Inc | Chemical products |
| AU539563B2 (en) * | 1981-01-21 | 1984-10-04 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara | Primycin, doxycyline and sisomicin composition |
Non-Patent Citations (1)
| Title |
|---|
| "The Merck Index", édition 10, 1983, pages 85,929,1093, Merck & Co., Inc., Rahway, NJ, US * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1989003672A1 (en) | 1989-05-05 |
| AU2624888A (en) | 1989-05-23 |
| FR2621818B1 (en) | 1990-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2621818A1 (en) | MEDICINE COMPRISING THE COMBINATION OF POLYMIXIN B, NETILMICIN AND AMPHOTERICIN B BY VAPORIZATION | |
| FR2621817A1 (en) | DRUG COMPRISING POLYMYXIN B, TOBRAMYCIN AND AMPHOTERICIN B VAPORIZED | |
| FR2624015A1 (en) | MEDICINE COMPRISING THE COMBINATION OF COLISTINE, TOBRAMYCIN AND AMPHOTERICIN B VAPORIZED | |
| ES2330415T3 (en) | SYSTEM FOR OSMOTIC SUPPLY OF PHARMACEUTICAL ACTIVE AGENTS. | |
| KR900012591A (en) | Delivery device for oral administration | |
| KR880013586A (en) | Dosage device comprising a removable substrate with a solid state property | |
| CA2039456A1 (en) | Osmotic dosage system for liquid drug delivery | |
| KR880002502A (en) | Formulations for Administration of Beneficial Acid Sensitive Agents | |
| ES2104522T3 (en) | NEW MEDICINAL ADMINISTRATION SYSTEM. | |
| ES2041174T3 (en) | INTRAVENOUS SYSTEM TO SUPPLY A BENEFICIAL AGENT. | |
| WO2000018447A3 (en) | Multiplex drug delivery system suitable for oral administration | |
| DK0998916T3 (en) | Medicines for administration to the mucosa | |
| US4876283A (en) | Antisnoring agent | |
| DK0652744T3 (en) | Pharmaceutical agents for delivering peptides through the mucosa | |
| BE900749A (en) | MICROENCAPSULE DRUG IN A SWEET MATRIX. | |
| PT2101730E (en) | Galenic form for the transmucosal delivery of paracetamol | |
| CA2433833A1 (en) | Use of flumazenil in developing a drug for the treatment of alcohol dependence | |
| CA1223210A (en) | Antisnoring agent | |
| KR970032872A (en) | Drugs for the treatment of skin damage containing acetylsalicylic acid | |
| WO2001008662A1 (en) | Liquid pharmaceutical composition based on paracetamol | |
| FR2624017A1 (en) | Medicament comprising a combination of colistin, amikacin and amphotericin B administered by vaporisation | |
| FR2622113A1 (en) | Medicament comprising a combination of polymyxin B, amikacin and amphotericin B administered by vaporisation | |
| JP2002068963A (en) | Liquid agent and container | |
| US10814076B2 (en) | Method for enhancing eustachian tube patency and treatment of otitis media | |
| FR2624738A1 (en) | Medicament comprising a combination of colistin, sissomicin and amphotericin B administered by vaporisation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |